AYTU BIOPHARMA, INC
Aytu BioPharma, Inc. (Nasdaq: AYTU) is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases. The company's website is www.aytu.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What AYTU BIOPHARMA, INC does
In the company’s own words
Aytu BioPharma, Inc. (Nasdaq: AYTU) is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases. The company's website is www.aytu.com.
Aytu operates as a single business segment specializing in prescription pharmaceutical products distributed through third-party intermediaries, wholesalers, and pharmacies. The company's commercial portfolio consists of three primary product lines. EXXUA, a novel first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for treating major depressive disorder in adults, represents the centerpiece of Aytu's current commercialization strategy following its launch in fiscal 2026. The company generated $6.6 million in EXXUA revenue during the fiscal year ended June 30, 2026. The ADHD Portfolio comprises Adzenys XR-ODT, an amphetamine extended-release orally disintegrating tablet, and Cotempla XR-ODT, a methylphenidate extended-release orally disintegrating tablet, both utilizing proprietary microparticle modified-release drug delivery technology. These products generated $45.8 million in revenue during fiscal 2026. The Pediatric Portfolio includes Karbinal ER, an extended-release carbinoxamine oral suspension for treating allergic conditions, which contributed $5.1 million in revenue.
For fiscal 2026, Aytu reported total net revenue of $57.6 million. The company employs 76 people as of June 30, 2026, and operates approximately 40 sales territories for EXXUA promotion. Aytu maintains proprietary intellectual property including composition-of-matter and method-of-use patents for its products, with key patents protecting Adzenys through 2032 and Cotempla through 2038. The company manufactures products through contract manufacturing organizations, including a United States-based manufacturer for ADHD products and Fabre-Kramer for EXXUA supply.
Aytu's strategic approach emphasizes acquiring, developing, and commercializing differentiated branded CNS products while leveraging its proprietary Aytu RxConnect patient access platform. The company previously divested its Consumer Health business in fiscal 2025 to focus resources on prescription pharmaceuticals. Aytu has accumulated losses since inception, reporting a net loss of $14.3 million for fiscal 2026 and an accumulated deficit of $347.8 million as of June 30, 2026.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- DENVER, CO
- Fiscal year end
- June
- CIK
- 1385818
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2026 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns AYTU BIOPHARMA, INC — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · AYTU BIOPHARMA, INC’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do AYTU BIOPHARMA, INC and its peers compare on margins and cash generation over ten years?”
- “Where did five years of AYTU BIOPHARMA, INC's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in AYTU BIOPHARMA, INC's last four quarterly filings that the numbers alone won't show?”